Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Conditions
- Patients With Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 363
- Registration Number
- NCT06472245
- Locations
- 🇫🇷
Hôpital Michallon, La Tronche, Rhône, France
🇺🇸Clinical Research Advisors, LLC, Beverly Hills, California, United States
🇺🇸Clinical Research Advisors - Encino, Encino, California, United States
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
- Conditions
- Solid Advanced TumorLymphoma
- Interventions
- Drug: OSE-279 100mgDrug: OSE-279 300mgDrug: OSE-279 500mg
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT05751798
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
🇫🇷Institut de Cancerologie de l'Ouest, Saint-Herblain, France
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Biological: CoVepiT (OSE13E)
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT04885361
- Locations
- 🇧🇪
Center for Vaccinology (CEVAC),, Gent, Belgium
Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT04882007
- Locations
- 🇷🇺
Ekaterinburg City Clinical Hospital No. 14, Ekaterinburg, Russian Federation
🇧🇪Groupe Santé CHC - Clinique du Mont Légia, Liège, Belgium
🇧🇬Medical Center Medconsult Pleven - OOD, Pleven, Bulgaria
A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 116
- Registration Number
- NCT03990233
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Brussel, Brussel, Belgium
🇫🇷Hospital St Pierre, La Réunion, France
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 63
- Registration Number
- NCT03980080
- Locations
- 🇧🇪
SGS Life Sciences (SGS LS), Clinical Pharmacology Unit (CPU), Antwerp, Belgium
Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104
- Conditions
- Rheumatoid ArthritisComplication of Transplant
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT02800811
- Locations
- 🇧🇪
SGS Antwerpen, Antwerpen, Belgium
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 219
- Registration Number
- NCT02654587
- Locations
- 🇮🇱
Soroka University Medical Center, Be'er Sheva, Israel
🇫🇷Clinique Victor Hugo, Le Mans, France
🇫🇷Hôpital d'Instruction des Armées Bégin, Saint Mandé, France